Eisai US’ cover photo
Eisai US

Eisai US

Pharmaceutical Manufacturing

Nutley, NJ 138,856 followers

Breaking through in the therapeutic areas of oncology and neurology. View our community guidelines: https://bit.ly/3dkY

About us

At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US. Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.

Website
http://us.eisai.com
Industry
Pharmaceutical Manufacturing
Company size
1,001-5,000 employees
Headquarters
Nutley, NJ
Type
Public Company
Founded
1995
Specialties
Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer

Locations

Employees at Eisai US

Updates

  • View organization page for Eisai US

    138,856 followers

    At our recent Snack and Learn, Daphne Franks, an advocate against predatory marriage, shared a personal story about the importance of stronger laws to protect vulnerable adults with serious health conditions such as #dementia. The session highlighted how existing legal frameworks may not always protect those who are at risk. We’re proud to support patients and families through programs like Magnolia Purpose in Planning to help those in the Alzheimer’s disease and dementia community avoid difficult situations like Daphne’s. Thank you, Daphne, and all who joined us. #LifeAtEisai #AlzheimersDisease #EndAlz

    • No alternative text description for this image
  • The #ESMO25 Congress brings together researchers, clinicians, and advocates dedicated to transforming cancer care. We look forward to presenting clinical data, including in endometrial carcinoma and renal cell carcinoma, in Berlin. Our research portfolio includes long-term follow-up insights and innovative therapeutic approaches. We're excited to contribute to the scientific dialogue that drives progress for patients worldwide. Rooted in our human health care philosophy, everything we do centers on working to improve outcomes for those who need it most. Learn more about our #ESMO25 presentations by reading our press release: bit.ly/EisaiESMO2025

    • No alternative text description for this image
  • It’s estimated that nearly 317,000 women will be diagnosed with invasive breast cancer in 2025. While we can’t control every factor, understanding your individual risk can empower you to make proactive choices for your health. This includes knowing your family’s medical history, as genetics can play a significant role. Early detection can make all the difference. By having regular conversations with your health care provider, you can create a personalized plan for prevention and screening. During #BreastCancerAwarenessMonth, take charge of your well-being by scheduling a check-up to discuss your risk factors and screening options today.

Similar pages

Browse jobs